Cargando…

Off-label caplacizumab as add-on therapy in a 9-year-old boy with refractory aTTP

Detalles Bibliográficos
Autores principales:	Veltroni, Marinella, Pegoraro, Francesco, Scappini, Barbara, Brugnolo, Francesca, Allegro, Elisa, Ermini, Stefano, Tondo, Annalisa, Fotzi, Ilaria, Bambi, Franco, Favre, Claudio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9072268/ https://www.ncbi.nlm.nih.gov/pubmed/34932149 http://dx.doi.org/10.1007/s00277-021-04740-4

Ejemplares similares

Relapsed Refractory Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Following COVID-19 Vaccination
por: Francisco, Michael T., et al.
Publicado: (2021)

Caplacizumab as frontline therapy in addition to standard treatment in iTTP
por: Cid, Joan, et al.
Publicado: (2022)

Successful Treatment of Refractory Thrombotic Thrombocytopenic Purpura (TTP) With Caplacizumab: A Case Report
por: Pramanik, Debolina, et al.
Publicado: (2023)

Case Report: Clinical and Hematological Characteristics of εγδβ Thalassemia in an Italian Patient
por: Fotzi, Ilaria, et al.
Publicado: (2022)

ATTP workshop at IdeaSquare
por: Poulaillon, Jimmy
Publicado: (2022)

P1609: CAPLACIZUMAB THERAPY IN OLDER PATIENTS (≥60 YEARS) WITH IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA (ITTP). RESULTS OF THE SPANISH TTP REGISTRY
por: Rubia, Javier DE LA, et al.
Publicado: (2023)

Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Caplacizumab for thrombotic thrombocytopenic purpura
Publicado: (2020)

Correction to: Caplacizumab: First Global Approval
por: Duggan, Sean
Publicado: (2018)

Caplacizumab for Acute Thrombotic Thrombocytopenic Purpura
por: Katsivalis, Katherine V., et al.
Publicado: (2021)

Caplacizumab: frequent local skin reactions
por: Kaufeld, Jessica, et al.
Publicado: (2020)

Long‐term follow‐up of patients treated with caplacizumab and safety and efficacy of repeat caplacizumab use: Post‐HERCULES study
por: Scully, Marie, et al.
Publicado: (2022)

Targeted treatment of solid tumors in pediatric precision oncology
por: Bertacca, Ilaria, et al.
Publicado: (2023)

Refractory Auto-Immune Thrombotic Thrombocytopenic Pupura Successfully Treated With Caplacizumab
por: Mellaza, Chloé, et al.
Publicado: (2020)

Human platelet lysate in mesenchymal stromal cell expansion according to a GMP grade protocol: a cell factory experience
por: Becherucci, Valentina, et al.
Publicado: (2018)

Generation of Drosophila attP containing cell lines using CRISPR-Cas9
por: Mariyappa, Daniel, et al.
Publicado: (2021)

Prolonged Exposure to Caplacizumab as Rescue Therapy in Refractory Immune Thrombotic Thrombocytopenic Purpura
por: Rodgers, George M, et al.
Publicado: (2023)

Successful Use of Bortezomib in an Adolescent with Refractory TTP
por: Wali, Junaid Ahmad, et al.
Publicado: (2023)

Autoimmune Cytopenias and Dysregulated Immunophenotype Act as Warning Signs of Inborn Errors of Immunity: Results From a Prospective Study
por: Schiavo, Ebe, et al.
Publicado: (2022)

Caplacizumab in adult patients with acquired thrombotic thrombocytopenic purpura
por: Hanlon, Ashley, et al.
Publicado: (2020)

Shared decision making, thrombotic thrombocytopenic purpura, and caplacizumab
por: Sukumar, Senthil, et al.
Publicado: (2020)

The Drosophila melanogaster attP40 docking site and derivatives are insertion mutations of msp-300
por: van der Graaf, Kevin, et al.
Publicado: (2022)

Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
por: Elverdi, Tugrul, et al.
Publicado: (2019)

Parallel Genomic Engineering of Two Drosophila Genes Using Orthogonal attB/attP Sites
por: Blanco-Redondo, Beatriz, et al.
Publicado: (2018)

The effect of Drosophila attP40 background on the glomerular organization of Or47b olfactory receptor neurons
por: Duan, Qichen, et al.
Publicado: (2023)

ADAMTS13, TTP and Beyond
por: Zheng, X Long
Publicado: (2012)

P1612: CALPROTECTIN LEVELS ARE ELEVATED IN CONGENITAL TTP AND IMMUNE TTP AT ADAMTS13 RELAPSE
por: Subhan, Maryam, et al.
Publicado: (2023)

Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?
por: Zheng, Lucy, et al.
Publicado: (2023)

Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter data
por: Gavriilaki, Eleni, et al.
Publicado: (2023)

More on the use of frontline caplacizumab in immune-mediated thrombotic thrombocytopenic purpura
por: Picod, Adrien, et al.
Publicado: (2022)

Hydroxychloroquine, TTP, COVID-19, and SLE
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

P1664: IMPACT OF A PROTOCOL USING RITUXIMAB FOR PREVENTION OF RELAPSE IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA (ATTP)
por: Marín Sánchez, E., et al.
Publicado: (2022)

Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
por: Cilla, Nicolas, et al.
Publicado: (2020)

Outcomes in 1096 patients with severe thrombotic thrombocytopenic purpura before the Caplacizumab era
por: Van de Louw, Andry, et al.
Publicado: (2021)

Safe and Effective Administration of Caplacizumab in COVID-19-Associated Thrombotic Thrombocytopenic Purpura
por: Bruzzese, Antonella, et al.
Publicado: (2023)

Cytomegalovirus induced refractory TTP in an immunocompetent individual: a case report
por: Boteju, Medhini, et al.
Publicado: (2019)

Remission of Severe, Relapsed, and Refractory TTP after Multiple Cycles of Bortezomib
por: Pandey, Manu R., et al.
Publicado: (2017)

Analysis of ROQUIN, Tristetraprolin (TTP), and BDNF/miR-16/TTP regulatory axis in late onset Alzheimer’s disease
por: Asadi, Mohammad Reza, et al.
Publicado: (2022)

Extensive dental caries and periodontal disease in a child with GATA2 deficiency
por: Consonni, Filippo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5c4n7n55ed08jiov267o7rrv38